Innovative Cellular Therapeutics Holdings Ltd 4

What Happened Innovative Cellular Therapeutics Holdings Ltd, a reported 10% owner of Lyell Immunopharma (LYEL), transferred 76,000 shares of Lyell common stock on June 29, 2026. The shares were transferred for no cash consideration (reported price $0.00) as a broker commission, so there were no proceeds to the reporting person. After the transfer, the reporting person beneficially owned approximately 2,857,500 shares (2,933,500 before the transfer).

Key Details

• Transaction date: 2026-06-29; Form 4 filed 2026-07-01.
• Transaction type/code: Other disposition (code J) — transfer of shares for no cash consideration.
• Shares transferred: 76,000 at $0.00; total reported value $0.
• Shares owned after transaction: ~2,857,500 common shares.
• Footnotes: F1 — shares transferred to Wuxiong, Inc. as broker commission related to an Upfront Payment under a License Agreement (dated Nov 6, 2025). F2 — ownership numbers reflect the pre-transfer and post-transfer counts.
• No late filing indication in the form (filed July 1, 2026).

Context This was an institutional transfer (10% owner) of stock as a broker commission tied to a license agreement, not an open-market sale or purchase by an executive. Transfers made to pay broker fees or similar obligations are routine and do not necessarily signal management sentiment about the company. No cash changed hands in this transaction.